Guest guest Posted June 11, 2008 Report Share Posted June 11, 2008 Dear Friends, Government of India now has come up with latest guidelines by NICD on Antirabies prophylaxis, but paradoxically again these guidelines say that " The vaccine package leaflet should include a statement indicating that the potency as well as immunogenicity and safety allow safe use of vaccine by ID pre- and post-exposure. " Again the guidelines are in the hands of the vaccine manufactureres as until they write in heir package insert that the vaccine is fit for I/D Route, we can not give it! This is the mockery of the intradermal order of DCGI, why not the DCGI forces these companies to write in the insert for intradermal use also? Again fight need to continue until DCGI does that. Please suggest. Dr. Omesh Bharti, Himachal A clip is beelow: General guidelines for use of IDRV (NICD) & #61548; Vaccines to be applied by intra-dermal route of administration should be approved by DCGI. & #61548; The vaccine package leaflet should include a statement indicating that the potency as well as immunogenicity and safety allow safe use of vaccine by ID pre- and post-exposure. & #61548; Post Marketing Surveillance (PMS) data should be maintained for minimum of two years by vaccine manufacturers on a pre-designed and approved protocol. & #61548; Intra-dermal injections must be administered by staff trained in this technique. & #61548; Vaccine vials must be stored at 2º to 8ºC after reconstitution. & #61548; The total content of reconstitute vial should be used as soon as possible, but at least with in 8 hours. & #61548; All the reconstituted vaccines should be discarded after 8 hours of reconstitution at the end of the day. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.